Celltrion, Inc. and CSL Ltd., an Australian biopharmaceutical company, have signed an agreement for the development and supply of CSL 360, an experimental monoclonal antibody for the treatment of acute myeloid leukemia (AML). CSL is currently conducting Phase I trials for the drug in Australia.
Celltrion, a Korean biopharma CMO, will provide process development expertise and supply clinical and commercial material to support the development program and commercialization of the drug. Under the agreement, the two companies may extend the manufacturing relationship in the future.
"Celltrion and its employees are completely committed to world-class quality in biopharmaceutical manufacturing, to assisting CSL in achieving the successful completion of clinical trials, and to providing manufacturing support for CSL's product commercialization," said Jung-Jin Seo, Celltrion's chairman and chief executive officer.
"Superior quality biopharmaceutical manufacturing facilities of this type are a scarce commodity in this region and we are delighted to have signed this collaboration to provide CSL with the opportunity to facilitate the clinical development of CSL 360 and potentially other exciting future recombinant protein opportunities," said Dr. Brian McNamee, CSL's chief executive officer.